Tony DeFusco started his career with MedImmune, Inc., where he worked in analytical development for products such as Synagis®, a monoclonal antibody for prevention of RSV, and Flumist®, a live attenuated virus vaccine. Tony went on to roles of increased responsibility in method development, manufacturing, Quality Assurance and Quality Control with a number of biotech companies. These included OxThera, Inc. (formerly Ixion-Biotechnology), developing a live bacteria therapeutic and a recombinant enzyme product for Kidney stone treatment and Banyan Biomarkers, Inc., a biotech company developing IVD devices and kits, as well as offering services from a GLP compliant testing lab, for the determination of Traumatic Brain Injury. His most recent role was the Director of cGMP compliance at Oragenics, Inc., a biotech company with a novel antibiotic in pre-clinical development and a marketed Probiotic for oral health, including EvoraPet® for companion animals.
Bachelors of Science in Microbiology (Minor in Chemistry), University of Florida
Masters of Science in Biotechnology, John Hopkins University